Search from website
Our cardiovascular biomarker antibodies are specifically engineered to help researchers and assay developers overcome complex analytical hurdles, including structural cross-reactivity, matrix interference, and the demand for sub-milligram limits of detection. While all clones undergo rigorous quality control for affinity and rapid binding kinetics, select pairs have been further internally validated using clinical human serum and platform-specific testing (CLIA/ELISA) to support reliable, matrix-stable performance in the next generation of high-sensitivity assays.
Select a target below to explore validated antibody pairs, analytical data, and available clones.
MYOCARDIAL INJURY
The Icosagen AdvantageOur 5F8 / 10C12 configuration is engineered for diagnostic applications requiring reliable performance in complex matrices. This pair has been internally validated via spike-and-recovery studies using clinical serum from Myocardial Infarction (MI) patients. For researchers seeking alternative high-affinity detection, the 5F8 capture antibody also demonstrates high synergy with our Rabbit Recombinant 26B5 detection clone. Lack of cross-reactivity to skeletal troponin I was confirmed with ELISA using native human skeletal muscle troponin I.
Cardiac Troponin I (cTnI) is the gold-standard biomarker for the clinical assessment of myocardial injury. Its rapid release following cardiomyocyte necrosis makes it critical for diagnostic algorithms, allowing clinicians to execute rapid rule-in and rule-out strategies for Acute Myocardial Infarction (AMI) in emergency cardiology (Collet et al., 2020 ESC Guidelines).
In circulation, cTnI exists in a heterogeneous state—frequently circulating as part of the binary (cTnI-TnC) or ternary (cTnI-TnC-cTnT) complexes, or subjected to various degrees of post-translational phosphorylation. To ensure diagnostic accuracy, antibody pairs must demonstrate high epitope accessibility across these diverse molecular forms to provide a representative measurement of total cTnI concentration (Thygesen et al., 2018).
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
5F8
|
10C12
|
CLIA
MI Patient Serum
Analytical Buffer
|
Spike & Recovery Validation: Confirmed using multiple MI patient serum donors (n=3). Demonstrates high epitope accessibility within the troponin complex and reliable recovery in pathological matrices. |
|
26B5 (Rb)
|
CLIA
Analytical Buffer
|
Linear Range Performance: Exhibits high linearity and consistent signal-to-noise ratios in standardized analytical buffer systems. | |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
MYOCARDIAL INJURY
The Icosagen Advantage Specific binding of antibodies to human cardiac troponin T and not to skeletal troponin T was confirmed by ELISA using native human skeletal muscle troponin T. When utilizing Clone 1D3 as the capture antibody with our high-affinity 1H11 detection antibody, this configuration provides a highly cardiac-specific signal. This pair has been internally validated via spike-and-recovery studies using clinical serum from Myocardial Infarction (MI) patients. This ensures robust, reliable translation into complex clinical matrices for your diagnostic assays.
Cardiac Troponin T (cTnT) is a critical biomarker for the assessment of myocardial injury and cardiac stress. Because it has a different release kinetic and half-life profile than cTnI, evaluating cTnT provides researchers and clinicians with a wider diagnostic window for assessing both acute ischemic events and chronic, low-grade myocardial damage (Thygesen et al., 2018).
A primary challenge in cTnT assay development is the structural homology between cardiac and skeletal isoforms. To prevent analytical over-recovery and potential false-positive elevations, antibody pairs must demonstrate high isoform specificity, particularly in patient populations with underlying skeletal muscle conditions (Byrne et al., 2023 ESC Guidelines).
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
1D3
|
1H11
|
CLIA
Analytical Buffer
MI Patient Serum
|
Clinical Validation & Specificity: Additionally validated in diluted human serum from myocardial infarction (MI) patients using spike and recovery methodologies. Optimized to minimize cross-reactivity with skeletal Troponin T (sTnT), demonstrating high analytical recovery and a clear cardiac-specific signal in complex clinical matrices. |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
Figure Source: Aimo A, et al. Biology and Clinical Application of Suppression of Tumorigenesis-2. J Am Coll Cardiol. 2019;74(17):2193-203. Link: https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1039
HEART FAILURE │ FIBROSIS & REMODELING
The Icosagen Advantage Our 2B6 / 21E3 pairing has been internally validated in human clinical serum to ensure robust performance in complex biological matrices. This configuration is optimized for high-sensitivity sandwich immunoassays, providing a precise tool for prognostic risk stratification research.
Soluble Suppression of Tumorigenicity 2 (sST2) is a key biomarker for the study of cardiac fibrosis, adverse remodeling, and heart failure progression. A distinct clinical advantage of sST2 is its relative independence from confounding factors such as age, BMI, and renal function, offering researchers a stable prognostic indicator that reflects the underlying mechanical and inflammatory stress on the myocardium (Heidenreich et al., 2022 AHA/ACC/HFSA Guidelines).
Accurately measuring sST2 requires overcoming significant matrix challenges. Assays must be precisely calibrated to isolate the soluble circulating biomarker in complex human serum without experiencing structural interference, competitive binding from endogenous proteins, or non-specific background noise (Dieplinger & Mueller, 2015).
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
2B6
|
21E3
|
CLIA
Human Serum
Analytical Buffer
|
Matrix Robustness: Validated for detection in clinical human serum. Demonstrates high analytical recovery and signal stability independent of patient demographics (age, BMI, renal function). |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
HEART FAILURE
The Icosagen Advantage Our Clone 22D5 is specifically selected for its robust recognition of proBNP variants, demonstrating minimal interference from common glycosylation sites. When paired with our high-affinity 20B11 detection antibody, this configuration ensures reliable analytical recovery in research populations with highly diverse glycosylation profiles.
Natriuretic peptides, including proBNP and its cleavage product NT-proBNP, are the definitive biomarkers for the diagnosis, staging, and prognostic monitoring of heart failure. Released by the myocardium in response to ventricular wall stress and volume overload, measuring these peptides allows researchers and clinicians to accurately assess the severity of hemodynamic compromise (Heidenreich et al., 2022 AHA/ACC/HFSA Guidelines).
A significant analytical challenge in proBNP research is the extensive O-glycosylation of the central region of the molecule. These sugar moieties can sterically mask critical epitopes and lead to severe analytical under-recovery. For consistent results, assay antibody pairs must demonstrate glycosylation-independent binding to provide a representative measurement across varying molecular patterns in different patient demographics (Semenov & Katrukha, 2016).
Figure Source: Natriuretic Peptides in Cardiovascular Disease. Springer Nature; 2024. Link: https://link.springer.com/chapter/10.1007/978-3-031-75686-3_11
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
22D5
|
20B11
|
CLIA
Analytical Buffer
|
Glycosylation-Insensitive Binding: Specifically selected for its ability to recognize both glycosylated and non-glycosylated variants. Minimizes steric hindrance effects, ensuring representative recovery of total proBNP. |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
Figure Source: D-Dimer Test. Cleveland Clinic. Link: https://my.clevelandclinic.org/health/diagnostics/22045-d-dimer-test
THROMBOSIS
The Icosagen Advantage Our Clone 8G2, Clone 2H6, and Clone 9D2 are meticulously selected to recognize the D-dimer neo-epitope, demonstrating no detectable cross-reactivity to fibrinogen. For maximum assay flexibility, our versatile detection partner 8G5 pairs seamlessly with 8G2, 2H6, and 9D2, ensuring high analytical specificity across various platform formats. Crucially, these matched pairs have been validated in diluted human serum using spike-and-recovery methodologies.
D-dimer is a specific degradation product of cross-linked fibrin, serving as a crucial, highly sensitive biomarker for the activation of coagulation and fibrinolysis. Clinically, rapid and sensitive D-dimer assays are instrumental in emergency diagnostic algorithms, primarily utilized for the rapid rule-out of Venous Thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Acute Pulmonary Embolism (PE) (Konstantinides et al., 2019 ESC Guidelines).
D-dimer research is vital for understanding thrombotic activity in vascular diseases and acute coronary syndromes. Accurate measurement is technically demanding, as it requires antibodies that can specifically distinguish cross-linked fibrin and FDP-X fragments from high background concentrations of circulating soluble fibrinogen (Adam et al., 2009).
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
2H6
|
8G5
|
CLIA
Analytical Buffer
Human Serum
|
High Fibrinogen Tolerance & Clinical Validation: Specifically recognizes the D-dimer neo-epitope with no detectable cross-reactivity to soluble fibrinogen. All three capture pairings are validated in diluted human serum using spike-and-recovery. |
|
8G2
|
CLIA
Analytical Buffer
Human Serum
|
||
|
9D2
|
CLIA
Analytical Buffer
Human Serum
|
||
| Matched pairs validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
INFLAMMATION
The Icosagen AdvantageOur Clone 2C7 and Clone 4D1 have been screened specifically for their sensitivity at the lower end of the detection spectrum. This pair provides the robust signal required for researchers developing high-sensitivity inflammation panels, ensuring reliable performance at critical sub-milligram concentrations.
C-Reactive Protein (CRP) is a foundational biomarker for cardiovascular risk profiling. It serves as a highly sensitive indicator of systemic inflammation and is a strong, independent predictor of future coronary events and the progression of atherosclerosis. Accurate measurement at the lower end of the concentration spectrum is critical for clinical risk categorization (Ridker, 2019).
CRP is a pentameric protein composed of five identical subunits. To classify as a true high-sensitivity (hs-CRP) assay, antibody pairs must maintain a low limit of detection and a broad linear range to provide representative measurements without being overwhelmed by baseline noise in complex matrices (Ridker, 2019).
Figure Source: The Pathogenic Role of C-Reactive Protein in Cardiovascular Diseases. Biomedicines. MDPI; 2023. Link: https://www.mdpi.com/2227-9059/11/9/2444
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
4D1
|
2C7
|
CLIA
Analytical Buffer
|
hsCRP Sensitivity: Optimized for high-sensitivity CRP (hsCRP) thresholds. Demonstrates reliable detection and consistent signal recovery at the lower end of the concentration spectrum in standardized analytical buffer systems. |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
Figure Source: Frontiers in Cardiovascular Medicine. Frontiers; 2021. Link: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.722908/full
MYOCARDIAL INJURY
The Icosagen AdvantageOur Clone 8H9 is a high-performance primary antibody demonstrating no detectable cross-reactivity with FABP4 (adipocyte) or FABP5 (epidermal) isoforms. Its high analytical specificity and rapid binding kinetics (kon) make it an ideal candidate for researchers developing early-stage injury detection platforms where speed and isoform-selectivity are paramount.
Heart-type Fatty Acid Binding Protein (FABP3) is a low-molecular-weight cytosolic protein. Due to its small size and high concentration in cardiomyocytes, it is rapidly released into the circulation following myocardial stress, often detectable within 1–3 hours of symptom onset. This rapid kinetic profile makes it a highly valuable biomarker for early-rule-out research models of Acute Coronary Syndromes (ACS), frequently preceding the rise of traditional troponin markers (Byrne et al., 2023 ESC Guidelines).
The human body expresses nine distinct, tissue-specific FABP isoforms that share significant structural and sequence homology. For cardiac assay development, the primary analytical hurdle is ensuring absolute isoform specificity. Antibodies must perfectly distinguish the heart-type isoform (FABP3) from closely related proteins—such as adipocyte (FABP4) or epidermal (FABP5) types—to prevent false-positive elevations in patients with underlying metabolic or systemic conditions (Pelsers et al., 2005).
| Role | Clone | Validated Performance | Technical Data Summary |
|---|---|---|---|
| Primary Antibody |
8H9
|
ELISA
Analytical Buffer
|
Isoform Specificity & Kinetics: Demonstrates no detectable cross-reactivity with FABP4/FABP5 isoforms. Optimized for rapid association rates (kon) in standardized analytical buffer systems. |
| Internal validation performed via ELISA; customer-specific validation recommended for clinical matrix translation. | |||
FIBROSIS & REMODELING
The Icosagen AdvantageOur Galectin-3 clones 1B12 and 1G8 are rigorously screened, demonstrating no detectable cross-reactivity with Galectin-8 and Galectin-9. This high analytical specificity ensures that researchers can measure cardiac-related fibrosis accurately, minimizing potential interference from other systemic inflammatory pathways.
Galectin-3 plays a critical role in the pathophysiology of heart failure by promoting collagen deposition and myofibroblast proliferation. It serves as a key mediator and prognostic biomarker for cardiac fibrosis and adverse ventricular remodeling (de Boer et al., 2011).
As a member of the beta-galactoside-binding lectin family, Galectin-3 shares significant structural homology with other galectins circulating in human serum, particularly within the conserved carbohydrate recognition domain (CRD). A primary analytical challenge in assay development is achieving absolute target specificity, as cross-reactivity with structurally similar isoforms can lead to falsely elevated readings and obscure the cardiac-specific fibrotic signal (Christenson et al., 2010).
Figure Source: Translational Impact of Galectin-3 in Adverse Cardiac Remodeling. Clinica Chimica Acta. ScienceDirect; 2025. Link: https://www.sciencedirect.com/science/article/ abs/pii/S0009898125006564
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
1B12
|
1G8
|
CLIA
Analytical Buffer
|
High Isoform Specificity: Screened for specificity against related galectin family members, demonstrating no detectable cross-reactivity with Galectin-8 and Galectin-9 in standardized analytical buffer systems. |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
Figure Source: Antioxidants. MDPI; 2024. Link: https://www.mdpi.com/2076-3921/13/7/788
INFLAMMATION
The Icosagen Advantage Our MPO portfolio features the Clone 4D7 / Clone 4F4 pair, optimized for high-throughput vascular research. These recombinant antibodies are validated for reliable performance, ensuring researchers can monitor inflammatory progression with consistent structural recognition and high signal-to-noise ratios, effectively mitigating the background interference common in MPO assays.
Myeloperoxidase (MPO) is a leukocyte-derived enzyme that catalyzes the formation of reactive oxidants. It serves as a critical marker of plaque instability and neutrophil activation, providing a strong independent prediction of future cardiovascular events and systemic oxidative stress in high-risk research populations (Ridker, 2019).
A major analytical challenge in developing MPO immunoassays is managing its highly cationic (positively charged) biochemical nature. MPO readily adheres to assay surfaces and endogenous negatively charged proteins in complex human serum. This non-specific binding can lead to severe background noise, requiring highly specific antibodies to isolate the true MPO signal without cross-reacting with other homologous human peroxidases (Ndrepepa, 2014).
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
4D7
|
4F4
|
CLIA
Analytical Buffer
|
Signal Clarity: Optimized to mitigate non-specific binding in standardized assay environments. Verified for high-throughput compatibility, delivering high signal-to-noise ratios. |
| Matched pair validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
MYOCARDIAL INJURY
The Icosagen Advantage For researchers developing rapid-response diagnostic formats, antibody binding kinetics are a critical parameter. Our Myoglobin clones (8D5, 8G9, and 4B6) are specifically selected for their rapid association rates (kon). Furthermore, these clones have been validated in matched sandwich configurations, including validation in diluted human plasma using spike and recovery methodologies. This ensures reliable analytical recovery and robust signal generation in early-detection models.
Myoglobin is a small, oxygen-binding heme protein that is among the first biomarkers to rise following myocardial cell death. Due to its low molecular weight and rapid release kinetics, it becomes detectable in circulation within 1–2 hours of symptom onset. This makes it a vital tool for studying the early diagnostic window and is frequently incorporated into multi-marker research panels to confirm or rule out early-stage Acute Coronary Syndromes (Byrne et al., 2023 ESC Guidelines).
A primary analytical challenge with myoglobin is its lack of strict cardiac specificity, as it is also abundantly expressed in skeletal muscle, combined with its rapid renal clearance which creates a narrow testing window. To be effective, particularly in Point-of-Care Testing (POCT) and rapid-response formats, antibody pairs must possess exceptionally fast binding kinetics. This ensures the assay can capture the target and generate a robust signal during very short incubation times before the biomarker is cleared from the sample (Apple et al., 2012).
Figure Source: Molecule of the Month: Myoglobin. PDB-101 (RCSB Protein Data Bank). Link: https://pdb101.rcsb.org/motm/1
| Capture | Detection | Validated Pair Performance | Technical Data Summary |
|---|---|---|---|
|
8G9
|
8D5
|
CLIA
Analytical Buffer
Human Plasma
|
Rapid Kinetics & Matrix Validation:
Optimized for high association rates (kon) to facilitate rapid-response assay formats. Both pairings have been validated in diluted human plasma using spike and recovery methodologies, ensuring reliable diagnostic performance.
Note on Versatility: Clone 8D5 is a highly adaptable antibody, functionally verified as an efficient partner in both capture and detection orientations. |
|
8D5
|
4B6
|
CLIA
Analytical Buffer
Human Plasma
|
|
| Matched pairs validated via internal sandwich CLIA; customer-specific validation recommended for clinical matrix translation. | |||
Didn’t find the answer? Ask us a question!
Cardiovascular disease (CVD) remains the leading cause of mortality globally, necessitating high-precision analytical tools to study the complete continuum of cardiac pathology—from early ischemic events and systemic inflammation to adverse remodeling and thrombotic cascades.
Our recommended antibody pairs are rigorously validated internally using standardized sandwich CLIA and ELISA formats, often utilizing complex clinical matrices (such as human serum or plasma). However, all products are currently sold for Research Use Only (RUO). Customers are responsible for performing their own clinical matrix translation and regulatory validation for In Vitro Diagnostic (IVD) commercialization.
The products linked above are supplied as unconjugated primary antibodies to provide maximum flexibility for your specific platform. However, Icosagen offers comprehensive custom conjugation and antibody engineering services. Reach out to our technical support team to discuss your specific assay requirements.
Absolutely. While we provide our "Recommended Pairs" to accelerate your development, assay environments vary significantly. We encourage researchers to test various capture and detection orientations. If you need assistance selecting a panel of clones for optimization, our scientific support team is available for consultation.
To streamline assay optimization, we provide internally validated antibody pairs for cardiac assays for every target in our catalog. These specific capture and detection combinations have been rigorously screened in complex biological matrices (such as human serum) to demonstrate high analytical sensitivity, broad linear ranges, and minimal cross-reactivity.
Our portfolio supports assay development across various clinical research applications. We offer highly specific myocardial injury antibodies (such as FABP3, Myoglobin, and cTnI) evaluated for early-stage acute coronary syndrome (ACS) research models, alongside well-characterized heart failure biomarker antibodies (such as sST2, Galectin-3, and proBNP) utilized in chronic risk stratification and adverse remodeling studies.
© 2026 Icosagen
